1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process

 
• By Malcolm Spicer

The “Nonprescription Drug Product with an Additional Condition” for OTC use proposed rule would add to drug firms’ workloads for some OTC switches. Along with NDAs, sponsors would need to show a DFL isn’t sufficient to ensure a consumer can appropriately self-select and use a drug OTC and how an “additional condition” system would work.

The proposed rule was issued on 27 June and intended to broaden the range of nonprescription drugs available. • Source: Shutterstock

Increasing over-the-counter switches in the US will add “ACNU” to regulatory jargon and flexibility to the Food and Drug Administration’s drug approval process, allowing the same ingredient at the same dose to remain available for prescription after being approved for nonprescription sales, according to a proposed rule.

The FDA’s “Nonprescription Drug Product with an Additional Condition for Nonprescription Use” proposed rule published on 27 June –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More NME Reviews, Reduced Costs Combine To Lower US FDA Voucher Fee

 
• By Derrick Gingery

The FDA said new molecular entity application reviews increased and cost less in fiscal year 2024, a potentially encouraging sign for industry.

US FDA Complete Response Letters Offer ‘Path Forward’ To Approval

 
• By Sue Sutter

Recently released CRLs for unapproved products contain recommendations for new studies, including design element details and advice to consider different submission pathways.

US FDA Complete Response Letters Raise Confirmatory Evidence Shortfalls

 
• By Sue Sutter

The agency identified deficiencies in efficacy evidence intended to support results from a single adequate and well-controlled trial for orphan applications, including weaknesses in animal data and insufficient quantity and quality of biomarker data.

Diving Into US FDA’s Newly Public CRLs

 
• By Bridget Silverman

The Pink Sheet breaks down the data on the 89 complete response letters recently released by the FDA, including by type of application and problems noted.

More from Pathways & Standards

US FDA Complete Response Letters Offer ‘Path Forward’ To Approval

 
• By Sue Sutter

Recently released CRLs for unapproved products contain recommendations for new studies, including design element details and advice to consider different submission pathways.

Blueprint For RWE: Aetion Execs Outline Real-World Data Role From Preclinical To Postmarketing

 
• By Bridget Silverman

Sponsors should systematically incorporate real-world evidence generation in all development programs, advises an epidemiology-forward “blueprint” Aetion executives developed.

US FDA Complete Response Letters Raise Confirmatory Evidence Shortfalls

 
• By Sue Sutter

The agency identified deficiencies in efficacy evidence intended to support results from a single adequate and well-controlled trial for orphan applications, including weaknesses in animal data and insufficient quantity and quality of biomarker data.